- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07598734
Doxepin Alone or Combined With Ramelteon Versus Placebo for Improving Sleep Quality After Primary Total Knee Arthroplasty
Doxepin Versus Doxepin and Ramelteon Versus Placebo to Improve Sleep Quality After Primary Total Knee Arthroplasty: A Randomized Controlled Trial
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 4
Contatti e Sedi
Contatto studio
- Nome: Gerald Y Liao, MS
- Numero di telefono: 617-710-7211
- Email: liaog@uw.edu
Backup dei contatti dello studio
- Nome: Nicholas M Hernandez, MD
- Numero di telefono: 530-514-1275
- Email: nichern@uw.edu
Luoghi di studio
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98133
- University of Washington Medical Center Hip & Knee Center
-
Contatto:
- Portia Morgan
- Numero di telefono: 206-668-3674
- Email: morganp9@uw.edu
-
Investigatore principale:
- Nicholas M Hernandez, MD
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Descrizione
Inclusion Criteria:
- Those receiving primary total knee arthroplasty (TKA)
- 80 years or less, age 18 or greater
Exclusion Criteria:
- History of cardiovascular bundle branch block
- Actively taking selecrtive serotoin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), or having treatment via counseling/psychotherapy for major depression or anxiety, bipolar, or psychotic disorder
- Pre-operative narcotics (defined as more than 1 prescription in the past 3 months)
- Self-reported use of alcohol in excess of >2 drinks/day (in men) and > 1 drink/day (in women)
- Use of prescription sleep aids (e.g., Ambien, Trazadone) prior to surgery (i.e., melatonin or other OTC sleep aids are permitted)
- History of major sleep disorder (e.g., obstructive sleep apnea (OSA), restless leg syndrome, narcolepsy)
- Pregnant, breastfeeding or planning to become pregnant in the next 3 months post-surgery. No pregnancy testing will be performed; screening will rely solely on participant self-report.
- Unable to take the study medication(s) due to contraindications with other medications the patient uses
- Have been diagnosed with (or are at risk of) narrow-angle or angle-closure glaucoma. In order to be eligible, participants must be able to report that they have had their eyes dilated within the past year without problems.
- Have severe urinary retention or difficulty emptying your bladder.
- Had glaucoma-related eye procedures (e.g., laser iridotomy)
- Ongoing use of glaucoma eye drops.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Terapia di supporto
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Doxepin 6 mg
Participants receive doxepin 6 mg and matching placebo orally once nightly for sleep during the first 6 weeks postoperative period following total knee arthroplasty.
|
Doxepin 6 mg administered orally once nightly for sleep during the first 6 weeks of the postoperative period following total knee arthroplasty
|
|
Sperimentale: Doxepin 6 mg and Ramelteon 8mg
Participants receive doxepin 6 mg and ramelteon 8 mg orally once nightly for sleep during the first 6 weeks postoperative period following total knee arthroplasty.
|
Doxepin 6 mg administered orally once nightly for sleep during the first 6 weeks of the postoperative period following total knee arthroplasty
Ramelteon 8 mg administered orally once nightly for sleep during the first 6 weeks of the postoperative period following total knee arthroplasty
|
|
Comparatore placebo: Placebo
Participants receive 2 matching placebos orally once nightly for sleep during the first 6 weeks postoperative period following total knee arthroplasty.
|
Placebo administered orally once nightly for sleep during the first 6 weeks of the postoperative period following total knee arthroplasty
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Insomnia Severity Index (ISI) scores (sleep quality)
Lasso di tempo: Baseline; 2 weeks postoperatively; 6 weeks postoperatively; 3 months postoperatively
|
Insomnia Severity Index (ISI) The Insomnia Severity Index is a 7-item self-reported questionnaire assessing the nature, severity, and impact of insomnia.
Score categories:
|
Baseline; 2 weeks postoperatively; 6 weeks postoperatively; 3 months postoperatively
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Knee Injury and Osteoarthritis Outcome Score Physical Function Short Form (KOOS-PS)
Lasso di tempo: Baseline; 2 weeks postoperatively; 6 weeks postoperatively; 3 months postoperatively.
|
Knee Injury and Osteoarthritis Outcome Score Physical Function Short Form (KOOS-PS): The KOOS-PS is a 7-item patient-reported outcome measure assessing knee-related physical function, including activities such as rising from bed, putting on socks, rising from sitting, bending to the floor, twisting/pivoting, kneeling, and squatting . Each item is scored on a 5-point Likert scale (None to Extreme). Scores are transformed to a normalized scale ranging from 0 to 100, with higher scores indicating worse physical function (greater disability). |
Baseline; 2 weeks postoperatively; 6 weeks postoperatively; 3 months postoperatively.
|
|
Knee Injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS-JR)
Lasso di tempo: Baseline; 2 weeks postoperatively; 6 weeks postoperatively; 3 months postoperatively
|
Knee Injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS-JR): The KOOS-JR is a patient-reported outcome measure assessing knee pain, stiffness, and functional limitations during activities of daily living over the past week, including tasks such as twisting/pivoting, stair navigation, standing, rising from sitting, and bending . The instrument consists of 7 items scored on a 5-point Likert scale (None to Extreme). Raw scores (range 0-28) are summed and converted to an interval score ranging from 0 to 100, where 0 represents total knee disability and 100 represents perfect knee health (higher scores indicate better outcomes) |
Baseline; 2 weeks postoperatively; 6 weeks postoperatively; 3 months postoperatively
|
|
Patient-Reported Outcomes Measurement Information System Global-10 (PROMIS-10)
Lasso di tempo: Baseline; 2 weeks postoperatively; 6 weeks postoperatively; 3 months postoperatively
|
Patient-Reported Outcomes Measurement Information System Global-10 (PROMIS-10): The PROMIS-10 is a 10-item patient-reported outcome measure assessing global physical health, mental health, pain, fatigue, and social functioning. Items are scored on 5-point Likert scales (e.g., Excellent to Poor; Not at all to Very much), with one pain item scored from 0 to 10. Raw scores are summed and converted to standardized T-scores for Global Physical Health and Global Mental Health, each ranging approximately from 0 to 100 (mean 50, standard deviation 10), where higher scores indicate better health status |
Baseline; 2 weeks postoperatively; 6 weeks postoperatively; 3 months postoperatively
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
90-Day Hospital Readmission Status
Lasso di tempo: Within 90 days postoperatively
|
Hospital readmission status within 90 days following primary total knee arthroplasty, defined as any unplanned inpatient admission to a hospital occurring within 90 days after the index procedure.
This is a dichotomous outcome (Yes/No), where "Yes" indicates that a readmission occurred and represents a worse outcome.
|
Within 90 days postoperatively
|
|
Medication Compliance
Lasso di tempo: 2 weeks postoperatively; 6 weeks postoperatively
|
Medication Compliance: Medication adherence assessed using patient self-report and pill counts when feasible. Self-reported adherence is measured by patient-reported proportion of prescribed doses taken, and pill counts are used to calculate the percentage of medication consumed relative to the prescribed amount. Adherence is expressed as a percentage from 0 to 100%, where higher values indicate better compliance. |
2 weeks postoperatively; 6 weeks postoperatively
|
|
Length of Stay (LOS)
Lasso di tempo: Perioperative/Periprocedural
|
Length of Stay (LOS): Length of hospital stay following primary total knee arthroplasty, defined as the number of days from hospital admission to discharge (continuous variable, ≥0 days), where higher values indicate longer hospitalization (worse outcome). |
Perioperative/Periprocedural
|
|
Discharge Destination
Lasso di tempo: Perioperative/Periprocedural
|
Discharge Destination: Discharge disposition following primary total knee arthroplasty, categorized as home versus skilled nursing facility. This is a categorical outcome where discharge to a skilled nursing facility represents a worse outcome compared to discharge home. |
Perioperative/Periprocedural
|
|
Postoperative Mobility (Step Count)
Lasso di tempo: Perioperative/Periprocedural
|
Postoperative Mobility (Step Count): Postoperative mobility assessed by the number of steps taken during inpatient physical therapy sessions following primary total knee arthroplasty. Step count is recorded as the total number of steps ambulated (continuous variable, ≥0), where higher values indicate better functional recovery. |
Perioperative/Periprocedural
|
|
Level of Assistance Required for Ambulation
Lasso di tempo: Perioperative/Periprocedural
|
Level of Assistance Required for Ambulation: Level of assistance required during inpatient physical therapy following primary total knee arthroplasty, categorized as independent, 1-person assist, 2-person assist, or maximal assist. This is an ordinal outcome where greater assistance requirements indicate worse functional recovery. |
Perioperative/Periprocedural
|
|
Postoperative Falls
Lasso di tempo: Perioperative/Periprocedural; 3 months postoperatively
|
Postoperative Falls: Occurrence of patient falls during hospitalization or within the follow-up period after primary total knee arthroplasty, defined as any unintentional descent to the ground or lower level documented in the medical record.
This is a dichotomous outcome (Yes/No), where "Yes" indicates a fall occurred and represents a worse outcome.
|
Perioperative/Periprocedural; 3 months postoperatively
|
|
Postoperative Delirium
Lasso di tempo: Perioperative/Periprocedural; 3 months postoperatively
|
Occurrence of delirium during hospitalization or follow-up after primary total knee arthroplasty, defined by clinical documentation of acute confusional state or use of delirium-related precautions (e.g., 1:1 sitter, physical restraints).
This is a dichotomous outcome (Yes/No), where "Yes" indicates delirium occurred and represents a worse outcome.
|
Perioperative/Periprocedural; 3 months postoperatively
|
|
Pressure Ulcers (Bed Sores)
Lasso di tempo: Perioperative/Periprocedural; 3 months postoperatively
|
Pressure Ulcers (Bed Sores): Development of pressure ulcers during hospitalization or follow-up after primary total knee arthroplasty, defined as localized injury to the skin or underlying tissue documented in the medical record. This is a dichotomous outcome (Yes/No), where "Yes" indicates a pressure ulcer occurred and represents a worse outcome. |
Perioperative/Periprocedural; 3 months postoperatively
|
|
Postoperative Opioid Consumption (Morphine Milligram Equivalents)
Lasso di tempo: Perioperative/Periprocedural; 3 months postoperatively
|
Postoperative Opioid Consumption (Morphine Milligram Equivalents): Total postoperative opioid use following primary total knee arthroplasty, calculated as cumulative morphine milligram equivalents (MME) administered during hospitalization and follow-up. This is a continuous variable (≥0 mg), where higher values indicate greater opioid consumption (worse outcome). |
Perioperative/Periprocedural; 3 months postoperatively
|
|
Postoperative Medical Complications
Lasso di tempo: Perioperative/Periprocedural
|
Postoperative Medical Complications: Occurrence of medical complications following primary total knee arthroplasty, including myocardial infarction, venous thromboembolism, cerebrovascular accident, acute kidney injury, respiratory failure, urinary tract infection, pneumonia, gastrointestinal obstruction, and need for intensive care unit (ICU) admission during the same hospitalization. This is a composite dichotomous outcome (Yes/No), where "Yes" indicates that one or more complications occurred and represents a worse outcome. |
Perioperative/Periprocedural
|
|
Postoperative Surgical Complications
Lasso di tempo: Perioperative/Periprocedural; 3 months postoperatively
|
Occurrence of surgical complications following primary total knee arthroplasty, including reoperation, periprosthetic fracture, dislocation, infection, and postoperative stiffness.
This is a composite dichotomous outcome (Yes/No), where "Yes" indicates that one or more complications occurred and represents a worse outcome.
|
Perioperative/Periprocedural; 3 months postoperatively
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Nicholas M Hernandez, MD, University of Washington
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- STUDY00024373
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Doxepin 6 mg
-
Green Cross CorporationSymyooCompletatoNeutropenia indotta da chemioterapiaCorea, Repubblica di
-
University of PennsylvaniaTeva Branded Pharmaceutical Products R&D, Inc.Completato
-
Adynxx, Inc.National Institute on Drug Abuse (NIDA)Ritirato
-
University of AarhusAarhus University HospitalCompletatoObesità, addominaleDanimarca
-
Chulalongkorn UniversityNon ancora reclutamentoErrori di rifrazione
-
Weill Medical College of Cornell UniversityEisai Inc.Completato
-
SunovionCompletatoDisturbo da alimentazione incontrollataStati Uniti
-
Novartis PharmaceuticalsCompletatoMalattie degli occhi | Degenerazione maculare legata all'età | Degenerazione maculare | Degenerazione retinica | Malattie retiniche | Degenerazione maculare umidaStati Uniti, Porto Rico
-
NPO PetrovaxCompletatoInfezione respiratoria acutaFederazione Russa
-
Boehringer IngelheimCompletato